JP2017514871A - Ｎｍｄａｒ調節化合物の組合せ - Google Patents

Ｎｍｄａｒ調節化合物の組合せ Download PDF

Info

Publication number
JP2017514871A
JP2017514871A JP2016566909A JP2016566909A JP2017514871A JP 2017514871 A JP2017514871 A JP 2017514871A JP 2016566909 A JP2016566909 A JP 2016566909A JP 2016566909 A JP2016566909 A JP 2016566909A JP 2017514871 A JP2017514871 A JP 2017514871A
Authority
JP
Japan
Prior art keywords
nmdar antagonist
glyx
nmdar
group
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016566909A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514871A5 (enExample
Inventor
ジョーゼフ アール モスカル
ジョーゼフ アール モスカル
Original Assignee
ノースウェスタン ユニバーシティ
ノースウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ, ノースウェスタン ユニバーシティ filed Critical ノースウェスタン ユニバーシティ
Publication of JP2017514871A publication Critical patent/JP2017514871A/ja
Publication of JP2017514871A5 publication Critical patent/JP2017514871A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016566909A 2014-05-06 2015-05-06 Ｎｍｄａｒ調節化合物の組合せ Pending JP2017514871A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989183P 2014-05-06 2014-05-06
US61/989,183 2014-05-06
PCT/US2015/029477 WO2015171770A1 (en) 2014-05-06 2015-05-06 Combinations of nmdar modulating compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020083060A Division JP2020138973A (ja) 2014-05-06 2020-05-11 Ｎｍｄａｒ調節化合物の組合せ

Publications (2)

Publication Number Publication Date
JP2017514871A true JP2017514871A (ja) 2017-06-08
JP2017514871A5 JP2017514871A5 (enExample) 2018-06-14

Family

ID=54392956

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016566909A Pending JP2017514871A (ja) 2014-05-06 2015-05-06 Ｎｍｄａｒ調節化合物の組合せ
JP2020083060A Pending JP2020138973A (ja) 2014-05-06 2020-05-11 Ｎｍｄａｒ調節化合物の組合せ
JP2022116942A Pending JP2022159322A (ja) 2014-05-06 2022-07-22 Ｎｍｄａｒ調節化合物の組合せ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020083060A Pending JP2020138973A (ja) 2014-05-06 2020-05-11 Ｎｍｄａｒ調節化合物の組合せ
JP2022116942A Pending JP2022159322A (ja) 2014-05-06 2022-07-22 Ｎｍｄａｒ調節化合物の組合せ

Country Status (11)

Country Link
US (1) US20170072005A1 (enExample)
EP (1) EP3139943A4 (enExample)
JP (3) JP2017514871A (enExample)
KR (2) KR20220102662A (enExample)
CN (1) CN106659762A (enExample)
AU (1) AU2015256075B2 (enExample)
BR (1) BR112016025910A8 (enExample)
CA (1) CA2947976A1 (enExample)
MX (1) MX2016014581A (enExample)
RU (1) RU2721948C2 (enExample)
WO (1) WO2015171770A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519826A (ja) * 2018-04-04 2021-08-12 シャンハイ ジャンホー ファーマシューティカル アンド テクノロジー カンパニー リミテッド 芳香族化合物およびその製造方法と使用
JP2022520110A (ja) * 2019-02-14 2022-03-28 アルジャーノン・ファーマスーティカルズ・インコーポレイテッド 特発性肺線維症を治療するための組成物及び方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701853YA (en) 2014-09-15 2017-04-27 Rugen Holdings Cayman Ltd Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
WO2016049048A1 (en) * 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
EP3253761A4 (en) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
SI3297619T1 (sl) * 2015-05-22 2023-02-28 Vistagen Therapeutics, Inc., Terapevtske uporabe L-4-klorokinurenina
KR102613179B1 (ko) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 Nr2b nmda 수용체 길항제로서의 3,3-디플루오로피페리딘 카바메이트 헤테로사이클릭 화합물
CN108289884A (zh) * 2015-10-16 2018-07-17 塞西亚生物科学公司 用于治疗创伤性脑损伤的方法和组合物
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
WO2017205666A1 (en) * 2016-05-25 2017-11-30 National Health Research Institutes Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
EP3544610A1 (en) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
CN107550907A (zh) * 2017-08-29 2018-01-09 昆明医科大学 治疗精神分裂症的药物及验证药物的动物模型构建方法
EP3720464A1 (en) * 2017-12-05 2020-10-14 Naurex Inc. Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder)
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
CN109223785A (zh) * 2018-10-29 2019-01-18 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
CN113557028A (zh) * 2019-01-11 2021-10-26 诺雷克斯股份有限公司 雷帕替奈的盐和晶型
CA3155464A1 (en) 2019-10-28 2021-05-06 Mark Williams Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives
CN113234036B (zh) * 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途
KR20230056971A (ko) * 2021-10-21 2023-04-28 삼육대학교산학협력단 신규 케타민 유도체를 포함하는 우울증 예방 또는 치료용 약학적 조성물
US20240100062A1 (en) 2022-09-14 2024-03-28 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatment With an Iboga Alkaloid
WO2025065271A1 (en) * 2023-09-26 2025-04-03 Liangzhu Laboratory Methods and devices for treating depression
WO2025124571A1 (zh) * 2023-12-14 2025-06-19 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途
CN119174765A (zh) * 2024-09-04 2024-12-24 复旦大学附属中山医院 Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500238A (ja) * 2003-05-27 2007-01-11 フォーレスト ラボラトリーズ， インコーポレイテッド うつ病及びその他の気分障害のために、ｎｍｄａ受容体アンタゴニストと選択的セロトニン再取り込み阻害薬の併用
JP2008169223A (ja) * 1994-06-23 2008-07-24 Massachusetts Eye & Ear Infirmary 視神経炎の治療
JP2009519231A (ja) * 2005-11-25 2009-05-14 メルク シャープ エンド ドーム リミテッド Ｇｌｙｔ１阻害剤としてのアゼチジン誘導体
JP2012514006A (ja) * 2008-12-29 2012-06-21 バンダービルト ユニバーシティ ３．１．０二環式ＧｌｙＴ１阻害剤ならびにその作製および使用の方法
JP2013528629A (ja) * 2010-06-15 2013-07-11 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
PE20100094A1 (es) * 2008-07-03 2010-02-18 Amira Pharmaceuticals Inc Antagonistas heteroalquilo de receptores de prostaglandina d2
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008169223A (ja) * 1994-06-23 2008-07-24 Massachusetts Eye & Ear Infirmary 視神経炎の治療
JP2007500238A (ja) * 2003-05-27 2007-01-11 フォーレスト ラボラトリーズ， インコーポレイテッド うつ病及びその他の気分障害のために、ｎｍｄａ受容体アンタゴニストと選択的セロトニン再取り込み阻害薬の併用
JP2009519231A (ja) * 2005-11-25 2009-05-14 メルク シャープ エンド ドーム リミテッド Ｇｌｙｔ１阻害剤としてのアゼチジン誘導体
JP2012514006A (ja) * 2008-12-29 2012-06-21 バンダービルト ユニバーシティ ３．１．０二環式ＧｌｙＴ１阻害剤ならびにその作製および使用の方法
JP2013528629A (ja) * 2010-06-15 2013-07-11 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KAWABE K ET AL.: "Intrahippocampal D-cycloserine improves MK-801-induced memory deficits: radial-arm maze performance", BRAIN RESEARCH, vol. Vol.814, No.1-2, JPN6019001678, 1998, pages 226 - 230, ISSN: 0004187497 *
KISHI A ET AL.: "Concurrent activation of hippocampal glycine and polyamine sites of the N-methyl-D-aspartate recepto", NEUROSCIENCE LETTERS, vol. 257, no. 3, JPN6019001679, 1998, pages 131 - 134, ISSN: 0004187498 *
一谷 幸男 ほか: "ラット・マウスの空間認知・空間記憶における脳内グルタミン酸受容体の役割", 生理心理学と精神生理学, vol. 第２１巻，第１号, JPN6019001677, 2003, pages 5 - 17, ISSN: 0004187496 *
伊東 和真 ほか: "薬理学的特徴から予測できる副作用の分類・種類", 薬局, vol. 第６３巻，第２号, JPN6019001681, 2012, pages 273 - 277, ISSN: 0004187500 *
橋本 謙二: "うつ病の病態におけるグルタミン酸神経系の役割と新規治療薬の開発", 日本生物学的精神医学会誌, vol. 第２４巻，第３号, JPN6019001680, 2013, pages 153 - 156, ISSN: 0004187499 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519826A (ja) * 2018-04-04 2021-08-12 シャンハイ ジャンホー ファーマシューティカル アンド テクノロジー カンパニー リミテッド 芳香族化合物およびその製造方法と使用
JP7193178B2 (ja) 2018-04-04 2022-12-20 シャンハイ ジュゲン ファーマシューティカル アンド テクノロジー カンパニー リミテッド 芳香族化合物およびその製造方法と使用
US12351565B2 (en) 2018-04-04 2025-07-08 Shanghai Zhigen Pharmaceutical & Technology Co., Ltd. Aromatic compound and preparation method therefor and use thereof
JP2022520110A (ja) * 2019-02-14 2022-03-28 アルジャーノン・ファーマスーティカルズ・インコーポレイテッド 特発性肺線維症を治療するための組成物及び方法
JP7433331B2 (ja) 2019-02-14 2024-02-19 アルジャーノン・ファーマスーティカルズ・インコーポレイテッド 特発性肺線維症を治療するための組成物及び方法

Also Published As

Publication number Publication date
MX2016014581A (es) 2018-02-16
AU2015256075A1 (en) 2016-11-24
US20170072005A1 (en) 2017-03-16
CN106659762A (zh) 2017-05-10
CA2947976A1 (en) 2015-11-12
RU2016146714A3 (enExample) 2018-10-08
BR112016025910A2 (pt) 2017-08-15
KR20170013890A (ko) 2017-02-07
BR112016025910A8 (pt) 2021-07-13
RU2721948C2 (ru) 2020-05-25
AU2015256075B2 (en) 2021-02-25
WO2015171770A1 (en) 2015-11-12
RU2016146714A (ru) 2018-06-06
EP3139943A4 (en) 2018-07-18
JP2022159322A (ja) 2022-10-17
EP3139943A1 (en) 2017-03-15
JP2020138973A (ja) 2020-09-03
KR20220102662A (ko) 2022-07-20

Similar Documents

Publication Publication Date Title
JP2017514871A (ja) Ｎｍｄａｒ調節化合物の組合せ
JP5702288B2 (ja) Ｎｍｄａレセプターモジュレータ及びその用途
US10195179B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
RU2451512C2 (ru) Нейрогенез, опосредованный производным 4-ациламинориридина
EP2633868A1 (en) Combination of alpha 7 nicotinic agonists and antipsychotics
WO2011071136A1 (ja) 線維筋痛症治療剤
EA038339B1 (ru) Способы лечения аутизма
US20210128537A1 (en) T-type calcium channel modulators and methods of use thereof
JP2023133571A (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
JP2017524721A (ja) Ｎｍｄａ調節剤を使用するうつ病の治療方法
TW201808269A (zh) 用於治療搔癢症及／或發癢之方法
Liu et al. The potent analgesia of intrathecal 2R, 6R-HNK via TRPA1 inhibition in LF-PENS-induced chronic primary pain model
CN105209445B (zh) 治疗运动障碍和相关病症的方法
KR102033699B1 (ko) 치료 방법
US20230270693A1 (en) Molecular Targets for Modulation of Dissociative and Associative States
CA3007641C (en) Dbh inhibitors for treating or preventing memory loss
WO2010126527A1 (en) Methods of treating cns disorders
HK1237649A1 (zh) Nmdar调节化合物的组合
US20160038484A1 (en) Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RS57919B1 (sr) Trpc4 modulatori za primenu u lečenju ili prevenciji bola
US20200171128A1 (en) Compositions and methods for improving cognition
US20070167509A1 (en) Use of phenserine and analogs to treat behavioral problems and improve trainability
RU2802972C2 (ru) Фармацевтическая комбинация атипичного антипсихотика и модулятора nmda для лечения шизофрении, биполярного расстройства, когнитивного нарушения и клинической депрессии
EP3429563A1 (en) Compositions and methods for treating compulsive-like behavior in a subject
WO2020146878A1 (en) Salt and crystalline forms of rapastinel

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200109